6 research outputs found
Recommended from our members
Data for 'The development of DUAL BRD4 and CBP/p300 degraders from ISOX-DUAL' thesis by Anthony Edmonds (2022)
ESI related to AE Edmonds' thesis entitled 'The Development of DUAL BRD4 and CBP/p300 Degraders From ISOX-DUAL' (published 21.03.2022)Contains 1H, 13C and other NMR spectra, HRMS, HPLC data and also scans of the original data.AbstractThe development of Heterobifunctional molecules in the field of targeted degradation is a hot topic, with various modalities appearing over the past 20 years, with examples such as; PROTACs, SNIPERs, dTAGs, HaloTags, AUTACS, ATTECs and LYTACs. In 2019 alone there were 107 PROTAC publications, an increase of 55 from the previous year. ISOX-DUAL is an inhibitor of both BRD4 (IC50 = 1.5 µM) and CBP/p300 (IC50 = 0.65 µM) bromodomains and, as such, is a useful chemical probe for research into epigenetics.2 The published and our in-house protocols toward this target molecule were poor yielding and not amenable to scale-up. Here, synthetic routes towards the title compound were re- investigated, and now achieves an overall yield of 42%, compared to the literature published 1%. Using literature co-crystal structures in the bromodomains of BRD4 and CBP/p300 of the, structurally similar, inhibitor BDOIA383, two solvent exposed exit vectors were discovered for potential linkage to E3 recruiters. ISOX-DUAL was then re-designed with the optimised synthetic route to afford two degrader precursors (3.07) and (3.27) which were designed through replacement of the N,N-dimethylpropylamine to a propyl carboxylic acid (3.07) and the replacement of the morpholine moiety to a piperazine (3.27). Degrader mimics (3.09, 3.29) were synthesised from these compounds and showed no loss in binding affinities to the bromodomains of BRD4 or CBP/p300. A small library of 20 ISOX-DUAL based degraders were synthesised, guided by predicted physiochemical properties. Select degraders (4.69-4.72) were subjected to cell-free ubiquitination assays, to which, confirmed induction of ubiquitination of the target. The 20 synthesised degraders were initially treated in HeLa cells and 4.68 caused a reduction in BRD4 (75%) and CBP (73%), the most potent degrader in this assay. The investigation goes on to highlight the importance of cell lines when assessing these compounds and describes a series of future experiments, which, should be performed.</p
Recommended from our members
[Editorial] Introduction to ‘Medicinal Chemistry Small Molecule Probes’
Gemma Nixon, Khondaker Miraz Rahman and John Spencer introduce the RSC Chemical Biology themed collection on ‘Medicinal Chemistry Small Molecule Probes’.</p
Recommended from our members
[Dataset] The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by which LA1011 may Improve the Prognosis of Alzheimer’s Disease
Data for paper published in Biomolecules 2023, 13(7), 105Â
The data sets are the results for the ITC experiments investigating the interactions between Hsp90, FKBP51 and LA1011. A data set constitutes an ITC file from a heat of dilution or interaction experiment. Data sets are processed by using a pair of experiments represented by a heat of dilution and interaction pair that have the same date stamp at the front of the file name.
'dil' in the filename denotes the heat of dilution. Heats of dilution are into buffer. After the date stamp the interacting partner proteins or small molecule is shown.Â
The data files require Origin software to access.
Abstract
 Â
Functional changes in chaperone systems play a major role in the decline of cognition and contribute to neurological pathologies, such as Alzheimer’s disease (AD). While such a decline may occur naturally with age or with stress or trauma, the mechanisms involved have remained elusive. The current models suggest that amyloid-β (Aβ) plaque formation leads to the hyperphosphorylation of tau by a Hsp90-dependent process that triggers tau neurofibrillary tangle formation and neurotoxicity. Several co-chaperones of Hsp90 can influence the phosphorylation of tau, including FKBP51, FKBP52 and PP5. In particular, elevated levels of FKBP51 occur with age and stress and are further elevated in AD. Recently, the dihydropyridine LA1011 was shown to reduce tau pathology and amyloid plaque formation in transgenic AD mice, probably through its interaction with Hsp90, although the precise mode of action is currently unknown. Here, we present a co-crystal structure of LA1011 in complex with a fragment of Hsp90. We show that LA1011 can disrupt the binding of FKBP51, which might help to rebalance the Hsp90-FKBP51 chaperone machinery and provide a favourable prognosis towards AD. However, without direct evidence, we cannot completely rule out effects on other Hsp90-co-chaprone complexes and the mechanisms they are involved in, including effects on Hsp90 client proteins. Nonetheless, it is highly significant that LA1011 showed promise in our previous AD mouse models, as AD is generally a disease affecting older patients, where slowing of disease progression could result in AD no longer being life limiting. The clinical value of LA1011 and its possible derivatives thereof remains to be seen.</p
Recommended from our members
Controlling the uptake and release of semiochemicals in channel-type metal-organic frameworks through pore expansion
Semiochemicals can be used to manipulate insect behaviour for sustainable pest management strategies, but their high volatility is a major issue for their practical implementation. Inclusion of these molecules within porous materials is a potential solution to this issue, as it can allow for a slower and more controlled release. In this work, we demonstrate that a series of Zr(IV) and Al(III) metal-organic frameworks (MOFs) with channel-type pores enable controlled release of three semiochemicals over 100 days by pore size design, with the uptake and rate of release highly dependent on the pore size. Insight from Grand Canonical Monte Carlo simulations indicates that this is due to weaker MOF-guest interactions per guest molecule as the pore size increases. These MOFs are all stable post-release and can be reloaded to show near-identical re-release profiles. These results provide valuable insight on the diffusion behaviour of volatile guests in MOFs, and for the further development of porous materials for sustainable agriculture applications.</p
Recommended from our members
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease. We discovered a noncovalent, nonpeptidic inhibitor scaffold with lead-like properties that is differentiated from current main protease inhibitors. Our approach leveraged crowdsourcing, machine learning, exascale molecular simulations, and high-throughput structural biology and chemistry. We generated a detailed map of the structural plasticity of the SARS-CoV-2 main protease, extensive structure-activity relationships for multiple chemotypes, and a wealth of biochemical activity data. All compound designs (>18,000 designs), crystallographic data (>490 ligand-bound x-ray structures), assay data (>10,000 measurements), and synthesized molecules (>2400 compounds) for this campaign were shared rapidly and openly, creating a rich, open, and intellectual property–free knowledge base for future anticoronavirus drug discovery.</p
Recommended from our members
Chirality: a Key Parameter in Chemical Probes
Many small molecule bioactive and marketed drugs are chiral. They are often synthesised from commercially available chiral building blocks. However, chirality is sometimes incorrectly assigned by manufacturers with consequences for the end user ranging from: experimental irreproducibility, wasted time on synthesising the wrong product and reanalysis, to the added cost of purchasing the precursor and resynthesis of the correct stereoisomer. Further on, this could lead to loss of reputation, loss of funding, to safety and ethical concerns due to potential in vivo administration of the wrong form of a drug. It is our firm belief that more stringent control of chirality be provided by the supplier and, if needed, requested by the end user, to minimise the potential issues mentioned above. Certification of chirality would bring much needed confidence in chemical structure assignment and could be provided by a variety of techniques, from polarimetry, chiral HPLC, using known chiral standards, vibrational circular dichroism, and x-ray crystallography. A few case studies of our brushes with wrong chirality assignment are shown as well as some examples of what we believe to be good practice.</p